<DOC>
	<DOCNO>NCT01416389</DOCNO>
	<brief_summary>The purpose study evaluate anti-tumor activity LY2523355 relative ixabepilone treatment metastatic locally recurrent breast cancer use change tumor size continuous measure response .</brief_summary>
	<brief_title>A Study LY2523355 Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Epothilones</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Have histologic cytologic diagnosis metastatic locally recurrent breast cancer amenable therapy give curative intent . Have measurable disease define Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 guideline . Have receive 2 prior standard cytotoxic chemotherapy regimens metastatic breast cancer , opinion investigator , appropriate candidate experimental therapy . Regimens receive neoadjuvant adjuvant setting count prior regimen . Have receive prior taxane neoadjuvant , adjuvant , metastatic setting . Have recover acute effect prior chemotherapy , hormonal therapy , radiation prior study enrollment . Have performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) scale . Have adequate organ function . Have Common Terminology Criteria Adverse Events ( CTCAE ) Grade 2 great ( moderate worse ) peripheral neuropathy Have second primary malignancy . Have symptomatic , untreated , uncontrolled central nervous system metastasis . Have receive autologous stem cell transplant follow highdose chemotherapy . Have serious preexist medical condition opinion investigator would preclude participation study . Have active symptomatic fungal , bacterial , and/or know viral infection include active human immunodeficiency virus viral hepatitis . Have previously receive LY2523355 another study investigate agent therapy ixabepilone ixabepilone contain regimen . Have history radiation therapy involve 25 % bone marrow . Have QTcF interval &gt; 470msec screen electrocardiogram ( ECG ) . Have QRS widen &gt; 120 msec screen ECG . Can change stop take strong Cytochrome P450 3A4 ( CYP3A4 ) inhibitor CYP3A4 inducer per ixabepilone label . Have hypersensitivity drug formulate CremophorÂ® EL per ixabepilone label .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Locally</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Breast</keyword>
	<keyword>Cancer</keyword>
</DOC>